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Abstract: Precision medicine aims to treat diseases with special consideration for the individual biological variability. 
Novel biomarkers (BM) are needed to predict therapeutic responses and to allow for the selection of suitable patients for 
treatment with certain drugs. However, the identification and validation of appropriate BMs is challenging. Close col-
laboration between different partners seems to be a key success factor. While the importance of partnerships and larger, 
well-established consortia in BM discovery such as the pharmaceutical industry and academic institutions is well un-
derstood and has been investigated in the past, the use of open-innovation models, also known as ‘crowd sourcing for 
biomarkers’, is still in its infancy. Crowd sourcing comprises of a — usually via internet — request for problem solution 
to an open group of users in a kind of an ‘open call’. The community (crowd) is asked to provide solutions. Since the 
application of the crowd sourcing method offers the possibility to collect as many as possible novel ideas from a broad 
community with different expertise, this approach is particularly promising for BM development. In this article we de-
scribe the first examples of open-innovation models, such as the ‘grants for targets’ (G4T) and biomarkers initiative 
‘InnoCentive’ (innovation/incentive) platform. They may be a fruitful basis for collaborative BM development in the 
future. 
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Introduction 
ack or inadequate therapeutic effects are major 
reasons for failures in drug discovery. The use 
of ‘biomarker (BM) stratified approaches’, 
meaning that drugs are developed for particular and 
susceptible patient subgroups only, is expected to in-
crease the number of medical approvals of such drugs. 
BMs may be effective tools to reduce attrition rates. 
Consequently, pharmaceutical companies started to 
invest significant efforts and money into BM stratified 
approaches. Besides the use of BM for patient strati-
fication by predicting prognosis, therapeutic and ad-
verse events, they may serve as surrogate markers for  
clinical endpoints. The overall goal of BM application 
in the clinical setting should be to increase drug effi-
cacy leading to above-average success rates in the 
clinical treatment. Since BMs are of increasing im-
portance in medicine and drug discovery, a higher 
need for identification and validation of suitable BMs 
can be expected[1–4]. This however, may be challeng-
ing. The reasons are manifold: physiological/patho-
physiological and biological aspects have to be con-
sidered, and different technological aspects as well 
regulatory requirements have to be included. There-
fore, complementary expertise and skills are required 
which may not be present in a single institution. In 
addition, the development of the BM may significantly  
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increase the total research and development costs, and 
sharing these costs by different partners may decrease 
the overall risk if a drug fails. Collaborations between 
academia, diagnostic and the pharmaceutical indus-
try, best in consortia seem to be essential for success-
ful biomarker discovery, development, and imple-
mentation. Indeed, collaborations between academic 
institutions and the diagnostics and pharmaceutical 
industry are increasingly being executed. These type 
of collaborations may help to improve research and 
development productivity in industry, as well as en-
able academic institutions to better exploit the transla-
tional potential of their research[5–9]. 
Along with the well-regulated collaborations 
between big partners, such as the pharmaceutical indus-
try and academic institutions which were reviewed 
previously[6,7], the cooperation with young academic 
groups and biotech companies may be a fruitful basis 
for the development of innovative technologies and 
novel BMs[10]. Initiation of such collaborations may 
be difficult, in particular when the experience of the 
smaller partners in the interaction with big pharma 
companies is limited. For the ‘big pharma’ in turn, it 
may be hard to find appropriate smaller partners. 
To encourage and support those potential smaller co-
operation partners in participating in a problem solu-
tion, the method of crowd sourcing was developed and 
first introduced by Jeff Howe[11]. The initial applica-
tion was in the Business to Consumer sector. In the 
original meaning, crowd sourcing comprised of a — 
usually via internet — request for problem solution to 
an open group of users in a kind of an ‘open call’. The 
community (the crowd) is asked to provide solutions 
and the winning idea is rewarded. 
Successful examples of this method such as the 
Procter & Gamble ‘Connect and develop’ portal 
(www.pgconnectdevelop.com) allows consumers to 
bring their ideas for product improvements or novel 
product ideas. According to Procter & Gamble, more 
than 50% of their product initiatives involve signifi-
cant collaboration with outside innovators. Now, 
pharma companies are piloting this approach in drug 
discovery currently with a prime focus on new mo-
lecular targets. However, open innovation may also be 
useful for other areas such as new application systems, 
digital solutions and value-based healthcare.  
Two pioneering approaches adopting the ‘crowd 
sourcing’ scheme have been launched for biomarkers 
so far, including the ‘InnoCentive platform’ and the 
‘Grants for targets and biomarkers initiative’. These 
two open innovation initiatives are highlighted in the 
following article.  
Crowd Sourcing in Drug Discovery 
The first company to introduce this concept in drug 
discovery was Eli Lilly with the establishment of the 
InnoCentive platform (www.innocentive.com). Or-
ganisations in need of answers (‘seekers’) post spe-
cific questions (‘challenges’) on an internet market-
place. The web community (‘solvers’) can then pro-
vide solutions to the challenge. For each challenge, the 
seeking company can select the ‘best’ solution and the 
winning solver transfers the IP to the seeker and gets 
in return a financial reward. InnoCentive is now an 
independent organisation with a solver community of 
more than 200,000 experts in approximately 20 coun-
tries. Beyond drug discovery companies, other organi-
sations such as SAP, Procter & Gamble, and the Rocke-
feller Foundation use the platform to find innovative 
solutions to their needs. Further crowd sourcing initia-
tives have followed in the past two years. In contrast 
to the ‘classical crowd sourcing’ concept, where the 
question is completed when an appropriate solution 
has been provided, the goal of business driven initia-
tives is to collect as many novel ideas as possible to be 
further pursued in a more collaborative approach[5]. 
The Use of the InnoCentive (innovation/incen-
tive) Platform for Biomarker Discovery 
The InnoCentive platform was established in 2001[5] 
(www.innocentive.com). It has a broad scope and is 
also comprised of BM challenges. For example, in 
2015, a seeker asked for a specific and sensitive BM 
that is highly associated with liver fibrosis and 
could be used as a surrogate for clinical efficacy and 
ideally guide treatment selection. Another BM chal-
lenge was set up in 2008 to find a BM for disease ac-
tivity of amyotrophic lateral sclerosis. This challenge 
attracted more than 1,000 teams who reviewed the 
prize criteria, and a total of 12 submissions were re-
ceived from seven different countries. The prize was 
awarded to two ‘solvers’, who came up with prelimi-
nary BMs. However, more data are needed to validate 
their results (www.ideaconnection.com). Due to lim-
ited public information, it is not possible to give a final 
assessment on the overall success of the platform with 
regard to BM challenges yet. 
The Grants for Targets and Biomarkers  
Initiative 
Another example for an open innovation approach in 
Lilla Landeck, Monika Lessl, Andreas Busch, et al. 
 
 Advances in Precision Medicine, vol 1, issue 2, 2016 3 
the BM field is Bayer’s ‘ Grants4targets’ (G4T) initia-
tive (www.grants4targets.com), which was established 
in 2009 as a new approach for academic institutions to 
apply for grant support to pursue ideas on novel drug 
targets. In 2011, it was expanded to include BMs. The 
process, summarized in Figure 1, is as follows: after a 
review process, grants are provided to perform focu-
sed experiments for further validation of the proposed 
targets and biomarkers. In addition to financial sup-
port, Bayer provides specific know-how about target 
validation and drug discovery. Experienced scientists 
are nominated as project partners and, depending on 
the projects, tools or specific models are provided. By 
December 2015, more than 1,000 applications have 
been received, and 126 were for BMs (i.e., 15.5% of all 
applications). Eighteen BM projects have had ap-
proved grants, focusing on BM identification and/or 
BM candidate generation in cardiological, oncological 
and gynaecological indications, most often by apply-
ing novel technologies[12–14]. Since the G4T program 
is quite young, it is too early to judge its ultimate suc-
cess for the identification and validation of BM. The 




Figure 1. Crowd sourcing as partnering model to tap into the 
expertise of a large scientific community. The challenge can be 
the search for novel targets, biomarkers, compounds or indica-
tions for known assets. Adapted from Lessl et al., 2011, Nature 
Reviews Drug Discovery, 10, 241–242[5]. 
Summary and Conclusion 
Open Innovation has been defined by H. Chesbrough[14] 
as the use of external and internal ideas and paths to 
create value. It has increasingly become popular and 
penetrated pioneering industries such as software, 
electronics or consumer industries[15]. Moreover, in 
the pharmaceutical industry, open innovation app-
roaches are gaining in importance due to the pressing 
need to overcome the innovation gap. For the initial 
exploration of a new biomarker candidate or a novel 
technology, an open innovation approach seems to be 
suitable. 
Crowd sourcing approaches, as described in this ar-
ticle, are an adequate approach to leverage the know- 
how of a large group of experts. To make it successful, 
key factors for open innovation approaches in drug 
discovery have to be taken into account (Table 1). It 
has to be carefully evaluated, whether the approach 
fits the challenge to be solved. Furthermore, an ade-
quate budget is needed to fund the external activities, 
which might become challenging in economically diff-
icult times. Also, internal resources to manage, sup-
port and complement external activities are required 
as well as an open mindset to ensure uptake of exter-
nal ideas. Based on our experiences and the feedback 
we received from grant recipients, key prerequisites 
for success in the BM area are a fast and efficient 
processing of the requests, a low bureaucratic burden 
to generate and grant the proposals, and a face-to-face 
contact to the supported scientists after grant approval. 
This is strengthened by the fact that the know-how on 
drug development in academia is often limited and an 
intensive exchange is required to generate awareness 
and understanding for the entire process. Permea-
ble boundaries and transparency in communication of 
 
Table 1. Key success factors for crowd sourcing initiatives in drug discovery 
Category Factors involved 
Strategic aspects Evaluate suitability of crowd sourcing approach 
Define clearly what you are looking for and what you can offer to the community 
Operational aspects Create awareness for initiative, e.g., advertisements in key journals and direct mailings to scientific societies or key 
leaders in the field, presentation at conferences 
Communicate the submission and evaluation processes in a transparent manner 
Submit ideas quickly and with confidence for technical processes 
Ensure a transparent IP policy 
Keep bureaucratic hurdles low  
Enthusiasm and Commitment Prepare organisation for take up of external ideas 
Generate enthusiasm and commitment on all levels 
Relationship Management Generate trust by open and continuous communication 
Establish trustful relationship with Principal Investigators 
Modified according to Lessl et al.: Crowd sourcing in drug discovery. Nature Reviews Drug Discoveries, 10, 241–242 (2011)[5]. 
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needs and strategic interests are essential prerequisites 
to enable open innovation. However, these approaches 
are successful only if they are part of an overall stra-
tegy on how to deal with external innovation[7]. Key 
Performance Indicators defined for each initiative 
will be helpful to evaluate performance. It has to be 
pointed out that crowd sourcing initiatives in drug 
discovery are still in their infancy. Whether they will 
have a substantial impact on the development of novel 
BMs has yet to be proven. The first experiences are 
quite encouraging. We found that this type of collabora-
tion attracts academic groups, offers the chance to get 
access to new partners and provides a valuable tool. 
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